ImmuneID

ImmuneID: Unlocking the complexity of human immune responses to enable precision immunology

Who is ImmuneID?

ImmuneID is a precision therapeutics company developing transformational first-in-class and best-in-class medicines across a range of systemic autoimmune diseases, as well as cancer and neurological disorders. Founded in late 2020 by Longwood Fund, ImmuneID is backed by top-tier biotechnology venture investors including Arch Venture Partners, Alta Partners, Pitango Healthtech Fund, Section 32, Alexandria Venture Investments, In-Q-Tel, Tekla Capital Management and Xfund. Our leadership team is composed of seasoned biotechnology leaders with a track record of success. ImmuneID is building an emerging pipeline focused on chronic diseases with enormous unmet medical need, with an initial focus on autoimmune diseases and oncology. ImmuneID Appoints Jessica Atkinson as Chief Business Officer October 17, 2022.

Boston, United States

1-10 Employees

Founding year: 2020

Keywords

Biotechnology

Therapeutics

Industries

Biotechnology

Contact of ImmuneID

City: Boston

State: Massachusetts

Country: United States

Frequently asked questions (FAQ) about ImmuneID

Where is ImmuneID located?

The company ImmuneID is located in Boston, Massachusetts, United States. It's worth noting that the company may has more corporate locations

How many employees does ImmuneID approximately have?

As of the latest available information ImmuneID has around 1-10 employees worldwide.

When was ImmuneID founded?

ImmuneID was founded in 2020

In which industries does ImmuneID mainly work?

The company ImmuneID has it's main focus in the industries of Biotechnology

What is the current company status of ImmuneID?

Based on the founding year and the amount of employees the company ImmuneID seems to be a Startup at the current state. Note that over time that status can change